<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32555376</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>09</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1474-1784</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>19</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nature reviews. Drug discovery</Title>
          <ISOAbbreviation>Nat Rev Drug Discov</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine.</ArticleTitle>
        <Pagination>
          <StartPage>480</StartPage>
          <EndPage>494</EndPage>
          <MedlinePgn>480-494</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41573-020-0070-z</ELocationID>
        <Abstract>
          <AbstractText>The Hippo pathway is an evolutionarily conserved signalling pathway with key roles in organ development, epithelial homeostasis, tissue regeneration, wound healing and immune modulation. Many of these roles are mediated by the transcriptional effectors YAP and TAZ, which direct gene expression via control of the TEAD family of transcription factors. Dysregulated Hippo pathway and YAP/TAZ-TEAD activity is associated with various diseases, most notably cancer, making this pathway an attractive target for therapeutic intervention. This Review highlights the key findings from studies of Hippo pathway signalling across biological processes and diseases, and discusses new strategies and therapeutic implications of targeting this pathway.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dey</LastName>
            <ForeName>Anwesha</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Discovery Oncology, Genentech, Inc., South San Francisco, CA, USA. dey.anwesha@gene.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Varelas</LastName>
            <ForeName>Xaralabos</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0002-2882-4541</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA. xvarelas@bu.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guan</LastName>
            <ForeName>Kun-Liang</ForeName>
            <Initials>KL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R21 HD094012</GrantID>
            <Acronym>HD</Acronym>
            <Agency>NICHD NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R35 CA196878</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 GM051586</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA217642</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL124392</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>06</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Nat Rev Drug Discov</MedlineTA>
        <NlmUniqueID>101124171</NlmUniqueID>
        <ISSNLinking>1474-1776</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000091262">TEA Domain Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C057182">TEAD1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000091102">YAP-Signaling Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C088374">YAP1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.3.-</RegistryNumber>
          <NameOfSubstance UI="D000217">Acyltransferases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.3.1.-</RegistryNumber>
          <NameOfSubstance UI="C108675">TAFAZZIN protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000217" MajorTopicYN="N">Acyltransferases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005355" MajorTopicYN="N">Fibrosis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000090683" MajorTopicYN="N">Hippo Signaling Pathway</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D044968" MajorTopicYN="N">Regenerative Medicine</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000091262" MajorTopicYN="N">TEA Domain Transcription Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014945" MajorTopicYN="N">Wound Healing</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000091102" MajorTopicYN="N">YAP-Signaling Proteins</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Competing interests. K.-L.G. is a co-founder and has an equity interest in Vivace Therapeutics, Inc. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict-of-interest policies. A.D. is an employee of Genentech and shareholder at Roche.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32555376</ArticleId>
        <ArticleId IdType="mid">NIHMS1661218</ArticleId>
        <ArticleId IdType="pmc">PMC7880238</ArticleId>
        <ArticleId IdType="doi">10.1038/s41573-020-0070-z</ArticleId>
        <ArticleId IdType="pii">10.1038/s41573-020-0070-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Jia J, Zhang W, Wang B, Trinko R &amp; Jiang J
The Drosophila Ste20 family kinase dMST functions as a tumor suppressor by restricting cell proliferation and promoting apoptosis. Genes Dev. 17, 2514–2519 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC218145</ArticleId>
            <ArticleId IdType="pubmed">14561774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Justice RW, Zilian O, Woods DF, Noll M &amp; Bryant PJ
The Drosophila tumor suppressor gene Warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev. 9, 534–546 (1995).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7698644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kango-Singh M
et al.
Shar-pei mediates cell proliferation arrest during imaginal disc growth in Drosophila. Development
129, 5719–5730 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12421711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pantalacci S, Tapon N &amp; Leopold P
The Salvador partner Hippo promotes apoptosis and cell-cycle exit in Drosophila. Nat. Cell Biol. 5, 921–927 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14502295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tapon N
et al.
Salvador promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell
110, 467–478 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12202036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Udan RS, Kango-Singh M, Nolo R, Tao C &amp; Halder G
Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. Nat. Cell Biol. 5, 914–920 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14502294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu S, Huang J, Dong J &amp; Pan D
hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with Salvador and Warts. Cell
114, 445–456 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12941273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu T, Wang W, Zhang S, Stewart RA &amp; Yu W
Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. Development
121, 1053–1063 (1995).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7743921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng Z, Moroishi T &amp; Guan KL
Mechanisms of Hippo pathway regulation. Genes Dev. 30, 1–17 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4701972</ArticleId>
            <ArticleId IdType="pubmed">26728553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dupont S
et al.
Role of YAP/TAZ in mechanotransduction. Nature
474, 179–183 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21654799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanconato F, Cordenonsi M &amp; Piccolo S
YAP/TAZ at the roots of cancer. Cancer Cell
29, 783–803 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6186419</ArticleId>
            <ArticleId IdType="pubmed">27300434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanchez-Vega F
et al.
Oncogenic signaling pathways in The Cancer Genome Atlas. Cell
173, 321–337.e10 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6070353</ArticleId>
            <ArticleId IdType="pubmed">29625050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan R, Kim NG &amp; Gumbiner BM
Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1. Proc. Natl Acad. Sci. USA
110, 2569–2574 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3574943</ArticleId>
            <ArticleId IdType="pubmed">23359693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Escudero R
et al.
Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway. Oral. Oncol. 79, 55–63 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29598951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamar JM
et al.
The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc. Natl Acad. Sci. USA
109, E2441–2450 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3443162</ArticleId>
            <ArticleId IdType="pubmed">22891335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee CK
et al.
Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation. Science
363, 644–649 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30733421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang CS
et al.
Glutamine-utilizing transaminases are a metabolic vulnerability of TAZ/YAP-activated cancer cells. EMBO Rep. 19, e43577 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5989844</ArticleId>
            <ArticleId IdType="pubmed">29661856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bianchi AB
et al.
High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc. Natl Acad. Sci. USA
92, 10854–10858 (1995).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC40529</ArticleId>
            <ArticleId IdType="pubmed">7479897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murakami H
et al.
LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 71, 873–883 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21245096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng X
et al.
Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell
25, 831–845 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4074519</ArticleId>
            <ArticleId IdType="pubmed">24882515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu FX
et al.
Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell
25, 822–830 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4075337</ArticleId>
            <ArticleId IdType="pubmed">24882516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanas MR
et al.
Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci. Transl. Med. 3, 98ra82 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21885404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanas MR
et al.
Mechanism of action of a WWTR1(TAZ)–CAMTA1 fusion oncoprotein. Oncogene
35, 929–938 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4983459</ArticleId>
            <ArticleId IdType="pubmed">25961935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antonescu CR
et al.
Novel YAP1–TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer
52, 775–784 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4089994</ArticleId>
            <ArticleId IdType="pubmed">23737213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhanasekaran SM
et al.
Transcriptome metaanalysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. Nat. Commun. 5, 5893 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4274748</ArticleId>
            <ArticleId IdType="pubmed">25531467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gujral TS &amp; Kirschner MW
Hippo pathway mediates resistance to cytotoxic drugs. Proc. Natl Acad. Sci. USA
114, E3729–E3738 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5422801</ArticleId>
            <ArticleId IdType="pubmed">28416665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghiso E
et al.
YAP-dependent AXL overexpression mediates resistance to EGFR inhibitors in NSCLC. Neoplasia
19, 1012–1021 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5683041</ArticleId>
            <ArticleId IdType="pubmed">29136529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee JE
et al.
Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance. Biochem. Biophys. Res. Commun. 474, 154–160 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27105908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kapoor A
et al.
Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell
179, 1239 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6941747</ArticleId>
            <ArticleId IdType="pubmed">31730860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shao DD
et al.
KRAS and YAP1 converge to regulate EMT and tumor survival. Cell
158, 171–184 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4110062</ArticleId>
            <ArticleId IdType="pubmed">24954536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin L
et al.
The Hippo effector YAP promotes resistance to RAF-and MEK-targeted cancer therapies. Nat. Genet. 47, 250–256 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4930244</ArticleId>
            <ArticleId IdType="pubmed">25665005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson FH
et al.
A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell
27, 397–408 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4398996</ArticleId>
            <ArticleId IdType="pubmed">25759024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen CDK &amp; Yi C
YAP/TAZ signaling and resistance to cancer therapy. Trends Cancer
5, 283–296 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6557283</ArticleId>
            <ArticleId IdType="pubmed">31174841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calses PC, Crawford JJ, Lill JR &amp; Dey A
Hippo pathway in cancer: aberrant regulation and therapeutic opportunities. Trends Cancer
5, 297–307 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31174842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nehme NT
et al.
MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T-cell survival. Blood
119, 3458–3468 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3824282</ArticleId>
            <ArticleId IdType="pubmed">22174160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdollahpour H
et al.
The phenotype of human STK4 deficiency. Blood
119, 3450–3457 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3325036</ArticleId>
            <ArticleId IdType="pubmed">22294732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du X
et al.
Mst1/Mst2 regulate development and function of regulatory T cells through modulation of Foxo1/Foxo3 stability in autoimmune disease. J. Immunol. 192, 1525–1535 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24453252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang F
et al.
The kinases NDR1/2 act downstream of the Hippo homolog MST1 to mediate both egress of thymocytes from the thymus and lymphocyte motility. Sci. Signal. 8, ra100 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26443704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dang TS
et al.
Defective leukocyte adhesion and chemotaxis contributes to combined immunodeficiency in humans with autosomal recessive MST1 deficiency. J. Clin. Immunol. 36, 117–122 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4769310</ArticleId>
            <ArticleId IdType="pubmed">26801501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu X
et al.
Mst1 kinase regulates the actin-bundling protein L-plastin to promote T cell migration. J. Immunol. 197, 1683–1691 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4992580</ArticleId>
            <ArticleId IdType="pubmed">27465533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du X
et al.
Hippo/Mst signalling couples metabolic state and immune function of CD8α+ dendritic cells. Nature
558, 141–145 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6292204</ArticleId>
            <ArticleId IdType="pubmed">29849151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li C
et al.
Dendritic cell MST1 inhibits TH17 differentiation. Nat. Commun. 8, 14275 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5296641</ArticleId>
            <ArticleId IdType="pubmed">28145433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katagiri K, Imamura M &amp; Kinashi T
Spatiotemporal regulation of the kinase Mst1 by binding protein RAPL is critical for lymphocyte polarity and adhesion. Nat. Immunol. 7, 919–928 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16892067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou D
et al.
The Nore1B/Mst1 complex restrains antigen receptor-induced proliferation of naive T cells. Proc. Natl Acad. Sci. USA
105, 20321–20326 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2600581</ArticleId>
            <ArticleId IdType="pubmed">19073936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mou F
et al.
The Mst1 and Mst2 kinases control activation of rho family GTPases and thymic egress of mature thymocytes. J. Exp. Med. 209, 741–759 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3328371</ArticleId>
            <ArticleId IdType="pubmed">22412158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geng J
et al.
The transcriptional coactivator TAZ regulates reciprocal differentiation of TH17 cells and Treg cells. Nat. Immunol. 18, 800–812 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28504697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stampouloglou E
et al.
Yap suppresses T-cell function and infiltration in the tumor microenvironment. PLoS Biol. 18, e3000591 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6980695</ArticleId>
            <ArticleId IdType="pubmed">31929526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ni X
et al.
YAP is essential for Treg-mediated suppression of antitumor immunity. Cancer Discov. 8, 1026–1043 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6481611</ArticleId>
            <ArticleId IdType="pubmed">29907586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thaventhiran JE
et al.
Activation of the Hippo pathway by CTLA-4 regulates the expression of Blimp-1 in the CD8+ T cell. Proc. Natl Acad. Sci. USA
109, E2223–E2229 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3421161</ArticleId>
            <ArticleId IdType="pubmed">22745171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S
et al.
YAP antagonizes innate antiviral immunity and is targeted for lysosomal degradation through IKKε-mediated phosphorylation. Nat. Immunol. 18, 733–743 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28481329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Q
et al.
Hippo signalling governs cytosolic nucleic acid sensing through YAP/TAZ-mediated TBK1 blockade. Nat. Cell Biol. 19, 362–374 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5398908</ArticleId>
            <ArticleId IdType="pubmed">28346439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo X
et al.
Single tumor-initiating cells evade immune clearance by recruiting type II macrophages. Genes Dev. 31, 247–259 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5358722</ArticleId>
            <ArticleId IdType="pubmed">28223311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang G
et al.
Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Discov. 6, 80–95 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4707102</ArticleId>
            <ArticleId IdType="pubmed">26701088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee BS
et al.
Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma. Biochem. Biophys. Res. Commun. 491, 493–499 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28684311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janse van Rensburg HJ
et al.
The Hippo pathway component TAZ promotes immune evasion in human cancer through PD-L1. Cancer Res. 78, 1457–1470 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29339539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim MH
et al.
YAP-induced PD-L1 expression drives immune evasion in BRAFi-resistant melanoma. Cancer Immunol. Res. 6, 255–266 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29382670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng J
et al.
Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells. Oncogene
36, 5829–5839 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28604752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miao J
et al.
YAP regulates PD-L1 expression in human NSCLC cells. Oncotarget
8, 114576–114587 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5777715</ArticleId>
            <ArticleId IdType="pubmed">29383103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramjee V
et al.
Epicardial YAP/TAZ orchestrate an immunosuppressive response following myocardial infarction. J. Clin. Invest. 127, 899–911 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5330722</ArticleId>
            <ArticleId IdType="pubmed">28165342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moroishi T
et al.
The Hippo pathway kinases LATS1/2 suppress cancer immunity. Cell
167, 1525–1539.e17 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5512418</ArticleId>
            <ArticleId IdType="pubmed">27912060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karpowicz P, Perez J &amp; Perrimon N
The Hippo tumor suppressor pathway regulates intestinal stem cell regeneration. Development
137, 4135–4145 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2990205</ArticleId>
            <ArticleId IdType="pubmed">21098564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaw RL
et al.
The Hippo pathway regulates intestinal stem cell proliferation during Drosophila adult midgut regeneration. Development
137, 4147–4158 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2990206</ArticleId>
            <ArticleId IdType="pubmed">21068063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Staley BK &amp; Irvine KD
Warts and Yorkie mediate intestinal regeneration by influencing stem cell proliferation. Curr. Biol. 20, 1580–1587 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2955330</ArticleId>
            <ArticleId IdType="pubmed">20727758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai J
et al.
The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev. 24, 2383–2388 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2964748</ArticleId>
            <ArticleId IdType="pubmed">21041407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barry ER
et al.
Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature
493, 106–110 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3536889</ArticleId>
            <ArticleId IdType="pubmed">23178811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gregorieff A, Liu Y, Inanlou MR, Khomchuk Y &amp; Wrana JL
Yap-dependent reprogramming of Lgr5+ stem cells drives intestinal regeneration and cancer. Nature
526, 715–718 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26503053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yui S
et al.
YAP/TAZ-dependent reprogramming of colonic epithelium links ECM remodeling to tissue regeneration. Cell Stem Cell
22, 35–49.e7 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5766831</ArticleId>
            <ArticleId IdType="pubmed">29249464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azzolin L
et al.
YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response. Cell
158, 157–170 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24976009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serra D
et al.
Self-organization and symmetry breaking in intestinal organoid development. Nature
569, 66–72 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6544541</ArticleId>
            <ArticleId IdType="pubmed">31019299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayyaz A
et al.
Single-cell transcriptomes of the regenerating intestine reveal a revival stem cell. Nature
569, 121–125 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31019301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grijalva JL
et al.
Dynamic alterations in Hippo signaling pathway and YAP activation during liver regeneration. Am. J. Physiol. Gastrointest. Liver Physiol. 307, G196–G204 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24875096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang C
et al.
Differences in Yes-associated protein and mRNA levels in regenerating liver and hepatocellular carcinoma. Mol. Med. Rep. 5, 410–414 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22012126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu L, Finegold MJ &amp; Johnson RL
Hippo pathway coactivators Yap and Taz are required to coordinate mammalian liver regeneration. Exp. Mol. Med. 50, e423 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5992983</ArticleId>
            <ArticleId IdType="pubmed">29303509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bai H
et al.
Yes-associated protein regulates the hepatic response after bile duct ligation. Hepatology
56, 1097–1107 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3431197</ArticleId>
            <ArticleId IdType="pubmed">22886419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Camargo FD
et al.
YAP1 increases organ size and expands undifferentiated progenitor cells. Curr. Biol. 17, 2054–2060 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17980593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu L
et al.
Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc. Natl Acad. Sci. USA
107, 1437–1442 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2824398</ArticleId>
            <ArticleId IdType="pubmed">20080689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varelas X
et al.
The Hippo pathway regulates Wnt/β-catenin signaling. Dev. Cell
18, 579–591 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20412773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou D
et al.
Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell
16, 425–438 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3023165</ArticleId>
            <ArticleId IdType="pubmed">19878874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benhamouche S
et al.
Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev. 24, 1718–1730 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2922501</ArticleId>
            <ArticleId IdType="pubmed">20675406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang N
et al.
The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev. Cell
19, 27–38 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2925178</ArticleId>
            <ArticleId IdType="pubmed">20643348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yimlamai D
et al.
Hippo pathway activity influences liver cell fate. Cell
157, 1324–1338 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4136468</ArticleId>
            <ArticleId IdType="pubmed">24906150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yovchev M
et al.
Experimental model for successful liver cell therapy by Lenti TTR-YapERT2 transduced hepatocytes with tamoxifen control of Yap subcellular location. Sci. Rep. 6, 19275 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4725878</ArticleId>
            <ArticleId IdType="pubmed">26763940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loforese G
et al.
Impaired liver regeneration in aged mice can be rescued by silencing Hippo core kinases MST1 and MST2. EMBO Mol. Med. 9, 46–60 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5210079</ArticleId>
            <ArticleId IdType="pubmed">27940445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lodge EJ
et al.
Homeostatic and tumourigenic activity of SOX2+ pituitary stem cells is controlled by the LATS/YAP/TAZ cascade. eLife
10.7554/eLife.43996 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.43996</ArticleId>
            <ArticleId IdType="pmc">PMC6461440</ArticleId>
            <ArticleId IdType="pubmed">30912742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hogan BL
et al.
Repair and regeneration of the respiratory system: complexity, plasticity, and mechanisms of lung stem cell function. Cell Stem Cell
15, 123–138 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4212493</ArticleId>
            <ArticleId IdType="pubmed">25105578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Z
et al.
MAPK-mediated YAP activation controls mechanical-tension-induced pulmonary alveolar regeneration. Cell Rep. 16, 1810–1819 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27498861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun T
et al.
TAZ is required for lung alveolar epithelial cell differentiation after injury. JCI Insight
10.1172/jci.insight.128674 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.128674</ArticleId>
            <ArticleId IdType="pmc">PMC6675554</ArticleId>
            <ArticleId IdType="pubmed">31211697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LaCanna R
et al.
Yap/Taz regulate alveolar regeneration and resolution of lung inflammation. J. Clin. Invest. 130, 2107–2122 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6486331</ArticleId>
            <ArticleId IdType="pubmed">30985294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szymaniak AD, Mahoney JE, Cardoso WV &amp; Varelas X
Crumbs3-mediated polarity directs airway epithelial cell fate through the Hippo pathway effector Yap. Dev. Cell
34, 283–296 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4536126</ArticleId>
            <ArticleId IdType="pubmed">26235047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahoney JE, Mori M, Szymaniak AD, Varelas X &amp; Cardoso WV
The Hippo pathway effector Yap controls patterning and differentiation of airway epithelial progenitors. Dev. Cell
30, 137–150 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6331061</ArticleId>
            <ArticleId IdType="pubmed">25043473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao R
et al.
Yap tunes airway epithelial size and architecture by regulating the identity, maintenance, and self-renewal of stem cells. Dev. Cell
30, 151–165 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4130488</ArticleId>
            <ArticleId IdType="pubmed">25043474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elbediwy A
et al.
Integrin signalling regulates YAP and TAZ to control skin homeostasis. Development
143, 1674–1687 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4874484</ArticleId>
            <ArticleId IdType="pubmed">26989177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schlegelmilch K
et al.
Yap1 acts downstream of α-catenin to control epidermal proliferation. Cell
144, 782–795 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3237196</ArticleId>
            <ArticleId IdType="pubmed">21376238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silvis MR
et al.
α-Catenin is a tumor suppressor that controls cell accumulation by regulating the localization and activity of the transcriptional coactivator Yap1. Sci. Signal. 4, ra33 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3366274</ArticleId>
            <ArticleId IdType="pubmed">21610251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beverdam A
et al.
Yap controls stem/progenitor cell proliferation in the mouse postnatal epidermis. J. Invest. Dermatol. 133, 1497–1505 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23190885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee MJ, Byun MR, Furutani-Seiki M, Hong JH &amp; Jung HS
YAP and TAZ regulate skin wound healing. J. Invest. Dermatol. 134, 518–525 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24108406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, Pasolli HA &amp; Fuchs E
Yes-associated protein (YAP) transcriptional coactivator functions in balancing growth and differentiation in skin. Proc. Natl Acad. Sci. USA
108, 2270–2275 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3038759</ArticleId>
            <ArticleId IdType="pubmed">21262812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>von Gise A
et al.
YAP1, the nuclear target of Hippo signaling, stimulates heart growth through cardiomyocyte proliferation but not hypertrophy. Proc. Natl Acad. Sci. USA
109, 2394–2399 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3289361</ArticleId>
            <ArticleId IdType="pubmed">22308401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xin M
et al.
Hippo pathway effector Yap promotes cardiac regeneration. Proc. Natl Acad. Sci. USA
110, 13839–13844 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3752208</ArticleId>
            <ArticleId IdType="pubmed">23918388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin Z
et al.
Cardiac-specific YAP activation improves cardiac function and survival in an experimental murine MI model. Circ. Res. 115, 354–363 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4104149</ArticleId>
            <ArticleId IdType="pubmed">24833660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ito M
et al.
Characterization of a small molecule that promotes cell cycle activation of human induced pluripotent stem cell-derived cardiomyocytes. J. Mol. Cell Cardiol. 128, 90–95 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30684499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hara H
et al.
Discovery of a small molecule to increase cardiomyocytes and protect the heart after ischemic injury. JACC Basic. Transl. Sci. 3, 639–653 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6234526</ArticleId>
            <ArticleId IdType="pubmed">30456335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bassat E
et al.
The extracellular matrix protein agrin promotes heart regeneration in mice. Nature
547, 179–184 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5769930</ArticleId>
            <ArticleId IdType="pubmed">28581497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morikawa Y
et al.
Actin cytoskeletal remodeling with protrusion formation is essential for heart regeneration in Hippo-deficient mice. Sci. Signal. 8, ra41 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4442128</ArticleId>
            <ArticleId IdType="pubmed">25943351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vite A, Zhang C, Yi R, Emms S &amp; Radice GL
α-Catenin-dependent cytoskeletal tension controls Yap activity in the heart. Development
145, dev149823 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5868989</ArticleId>
            <ArticleId IdType="pubmed">29467248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nowell CS
et al.
Chronic inflammation imposes aberrant cell fate in regenerating epithelia through mechanotransduction. Nat. Cell Biol. 18, 168–180 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6195194</ArticleId>
            <ArticleId IdType="pubmed">26689676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mindos T
et al.
Merlin controls the repair capacity of Schwann cells after injury by regulating Hippo/YAP activity. J. Cell Biol. 216, 495–510 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5294779</ArticleId>
            <ArticleId IdType="pubmed">28137778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao K
et al.
Muscle Yap is a regulator of neuromuscular junction formation and regeneration. J. Neurosci. 37, 3465–3477 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5373129</ArticleId>
            <ArticleId IdType="pubmed">28213440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng Y
et al.
Yap1 regulates multiple steps of chondrocyte differentiation during skeletal development and bone repair. Cell Rep. 14, 2224–2237 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26923596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu JK
et al.
An FAK–YAP–mTOR signaling axis regulates stem cell-based tissue renewal in mice. Cell Stem Cell
21, 91–106.e6 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5501749</ArticleId>
            <ArticleId IdType="pubmed">28457749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayashi S, Tamura K &amp; Yokoyama H
Yap1, transcription regulator in the Hippo signaling pathway, is required for Xenopus limb bud regeneration. Dev. Biol. 388, 57–67 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24491818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayashi S
et al.
Transcriptional regulators in the Hippo signaling pathway control organ growth in Xenopus tadpole tail regeneration. Dev. Biol. 396, 31–41 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25284091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mateus R
et al.
Control of tissue growth by Yap relies on cell density and F-actin in zebrafish fin regeneration. Development
142, 2752–2763 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6514408</ArticleId>
            <ArticleId IdType="pubmed">26209644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin AY &amp; Pearson BJ
Planarian yorkie/YAP functions to integrate adult stem cell proliferation, organ homeostasis and maintenance of axial patterning. Development
141, 1197–1208 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24523458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caliari SR
et al.
Stiffening hydrogels for investigating the dynamics of hepatic stellate cell mechanotransduction during myofibroblast activation. Sci. Rep. 6, 21387 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4764908</ArticleId>
            <ArticleId IdType="pubmed">26906177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mannaerts I
et al.
The Hippo pathway effector YAP controls mouse hepatic stellate cell activation. J. Hepatol. 63, 679–688 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25908270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szeto SG
et al.
YAP/TAZ are mechanoregulators of TGF-β–Smad signaling and renal fibrogenesis. J. Am. Soc. Nephrol. 27, 3117–3128 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5042658</ArticleId>
            <ArticleId IdType="pubmed">26961347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu F
et al.
Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol
308, L344–L357 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4329470</ArticleId>
            <ArticleId IdType="pubmed">25502501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piersma B
et al.
YAP1 Is a driver of myofibroblast differentiation in normal and diseased fibroblasts. Am. J. Pathol. 185, 3326–3337 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26458763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B
et al.
TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 22, 1962–1971 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2492741</ArticleId>
            <ArticleId IdType="pubmed">18579750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aikawa T, Gunn J, Spong SM, Klaus SJ &amp; Korc M
Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol. Cancer Ther. 5, 1108–1116 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16731742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang WT, Vayalil PK, Miyata T, Hagood J &amp; Liu RM
Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis. Am. J. Respir. Cell Mol. Biol. 46, 87–95 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3262658</ArticleId>
            <ArticleId IdType="pubmed">21852684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ledwozyw A
The effect of β-aminopropionitrile on bleomycin-induced lung injury in rats. Acta Physiol. Hung. 83, 91–99 (1995).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7544946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barry-Hamilton V
et al.
Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat. Med. 16, 1009–1017 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20818376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gokey JJ
et al.
Active epithelial Hippo signaling in idiopathic pulmonary fibrosis. JCI Insight
10.1172/jci.insight.98738 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.98738</ArticleId>
            <ArticleId IdType="pmc">PMC5926907</ArticleId>
            <ArticleId IdType="pubmed">29563341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Machado MV
et al.
Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease. J. Hepatol. 63, 962–970 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4575842</ArticleId>
            <ArticleId IdType="pubmed">26070409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen P
et al.
Pathogenesis of non-alcoholic fatty liver disease mediated by YAP. Hepatol. Int. 12, 26–36 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29330836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X
et al.
Hepatocyte TAZ/WWTR1 promotes inflammation and fibrosis in nonalcoholic steatohepatitis. Cell Metab. 24, 848–862 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5226184</ArticleId>
            <ArticleId IdType="pubmed">28068223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang M
et al.
Yap/Taz deletion in Gli+ cell-derived myofibroblasts attenuates fibrosis. J. Am. Soc. Nephrol. 28, 3278–3290 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5661271</ArticleId>
            <ArticleId IdType="pubmed">28768710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kramann R
et al.
Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell
16, 51–66 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4289444</ArticleId>
            <ArticleId IdType="pubmed">25465115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitani A
et al.
Transcriptional coactivator with PDZ-binding motif is essential for normal alveolarization in mice. Am. J. Respir. Crit. Care Med. 180, 326–338 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19498055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toyama T
et al.
Therapeutic targeting of TAZ and YAP by dimethyl fumarate in systemic sclerosis fibrosis. J. Invest. Dermatol. 138, 78–88 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5742036</ArticleId>
            <ArticleId IdType="pubmed">28870693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varelas X
et al.
TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat. Cell Biol. 10, 837–848 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18568018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiemer SE, Szymaniak AD &amp; Varelas X
The transcriptional regulators TAZ and YAP direct transforming growth factor β-induced tumorigenic phenotypes in breast cancer cells. J. Biol. Chem. 289, 13461–13474 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4036353</ArticleId>
            <ArticleId IdType="pubmed">24648515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan MW, Hinz B &amp; McCulloch CA
Mechanical induction of gene expression in connective tissue cells. Methods Cell Biol. 98, 178–205 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20816235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haak AJ
et al.
Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis. Sci. Transl. Med. 11, eaau6296 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7066514</ArticleId>
            <ArticleId IdType="pubmed">31666402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gill MK
et al.
A feed forward loop enforces YAP/TAZ signaling during tumorigenesis. Nat. Commun. 9, 3510 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6115388</ArticleId>
            <ArticleId IdType="pubmed">30158528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lagares D
et al.
Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis. Sci. Transl. Med. 9, eaal3765 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29237758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu-Chittenden Y
et al.
Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 26, 1300–1305 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3387657</ArticleId>
            <ArticleId IdType="pubmed">22677547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dasari VR
et al.
Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells. Oncotarget
8, 28628–28640 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5438678</ArticleId>
            <ArticleId IdType="pubmed">28404908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang C
et al.
Verteporfin inhibits YAP function through up-regulating 14–3-3σ sequestering YAP in the cytoplasm. Am. J. Cancer Res. 6, 27–37 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4759394</ArticleId>
            <ArticleId IdType="pubmed">27073720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H
et al.
Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1. Sci. Signal. 8, ra98 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4818013</ArticleId>
            <ArticleId IdType="pubmed">26443705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song S
et al.
A novel YAP1 inhibitor targets CSC-enriched radiation-resistant cells and exerts strong antitumor activity in esophageal adenocarcinoma. Mol. Cancer Ther. 17, 443–454 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5805581</ArticleId>
            <ArticleId IdType="pubmed">29167315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basu D
et al.
Identification, mechanism of action, and antitumor activity of a small molecule inhibitor of Hippo, TGF-β, and Wnt signaling pathways. Mol. Cancer Ther. 13, 1457–1467 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24694946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith SA
et al.
Antiproliferative and antimigratory effects of a novel YAP–TEAD interaction inhibitor identified using in silico molecular docking. J. Med. Chem. 62, 1291–1305 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6701825</ArticleId>
            <ArticleId IdType="pubmed">30640473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurppa KJ
et al.
Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway. Cancer Cell
37, 104–122.e12 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7146079</ArticleId>
            <ArticleId IdType="pubmed">31935369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santucci M
et al.
The Hippo pathway and YAP/TAZ-TEAD protein–protein interaction as targets for regenerative medicine and cancer treatment. J. Med. Chem. 58, 4857–4873 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25719868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gibault F, Sturbaut M, Bailly F, Melnyk P &amp; Cotelle P
Targeting transcriptional enhanced associate domains (TEADs). J. Med. Chem. 61, 5057–5072 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29251924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noland CL
et al.
Palmitoylation of TEAD transcription factors is required for their stability and function in Hippo pathway signaling. Structure
24, 179–186 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26724994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan P
et al.
Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway. Nat. Chem. Biol. 12, 282–289 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4798901</ArticleId>
            <ArticleId IdType="pubmed">26900866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pobbati AV
et al.
Targeting the central pocket in human transcription factor TEAD as a potential cancer therapeutic strategy. Structure
23, 2076–2086 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4660270</ArticleId>
            <ArticleId IdType="pubmed">26592798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bum-Erdene K
et al.
Small-molecule covalent modification of conserved cysteine leads to allosteric inhibition of the TEAD·Yap protein–protein interaction. Cell Chem. Biol. 26, 378–389.e13 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30581134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maeda T, Chapman DL &amp; Stewart AF
Mammalian vestigial-like 2, a cofactor of TEF-1 and MEF2 transcription factors that promotes skeletal muscle differentiation. J. Biol. Chem. 277, 48889–48898 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12376544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pobbati AV, Chan SW, Lee I, Song H &amp; Hong W
Structural and functional similarity between the VGLL1–TEAD and the YAP–TEAD complexes. Structure
20, 1135–1140 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22632831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vaudin P, Delanoue R, Davidson I, Silber J &amp; Zider A
TONDU (TDU), a novel human protein related to the product of vestigial (Vg) gene of Drosophila melanogaster interacts with vertebrate TEF factors and substitutes for Vg function in wing formation. Development
126, 4807–4816 (1999).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10518497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiao S
et al.
A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell
25, 166–180 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24525233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B
et al.
Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21, 2747–2761 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2045129</ArticleId>
            <ArticleId IdType="pubmed">17974916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noto A
et al.
Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ. Oncogene
36, 4573–4584 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28368399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin KC
et al.
Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation. Nat. Cell Biol. 19, 996–1002 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5541894</ArticleId>
            <ArticleId IdType="pubmed">28752853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magico AC &amp; Bell JB
Identification of a classical bipartite nuclear localization signal in the Drosophila TEA/ATTS protein scalloped. PLoS ONE
6, e21431 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3121794</ArticleId>
            <ArticleId IdType="pubmed">21731746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qi Y
et al.
A splicing isoform of TEAD4 attenuates the Hippo–YAP signalling to inhibit tumour proliferation. Nat. Commun. 7, ncomms11840 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4909989</ArticleId>
            <ArticleId IdType="pubmed">27291620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu V, Plouffe SW &amp; Guan KL
The Hippo pathway in organ development, homeostasis, and regeneration. Curr. Opin. Cell Biol. 49, 99–107 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6348871</ArticleId>
            <ArticleId IdType="pubmed">29316535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan F
et al.
Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration. Sci. Transl. Med. 8, 352ra108 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27535619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou D
et al.
Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc. Natl Acad. Sci. USA
108, E1312–E1320 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3241824</ArticleId>
            <ArticleId IdType="pubmed">22042863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin C, Yao E &amp; Chuang PT
A conserved MST1/2–YAP axis mediates Hippo signaling during lung growth. Dev. Biol. 403, 101–113 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4469623</ArticleId>
            <ArticleId IdType="pubmed">25912685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi Y
et al.
Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin. Cancer Res. 11, 1380–1385 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15746036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cordenonsi M
et al.
The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell
147, 759–772 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22078877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz-Martin J
et al.
Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer. Endocr. Relat. Cancer
22, 443–454 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25870251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan SW
et al.
A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. 68, 2592–2598 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18413727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Genome Atlas Research Network. et al.
Integrated genomic and molecular characterization of cervical cancer. Nature
543, 378–384 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5354998</ArticleId>
            <ArticleId IdType="pubmed">28112728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu T
et al.
Clinical significance of Yes-associated protein overexpression in cervical carcinoma: the differential effects based on histotypes. Int. J. Gynecol. Cancer
23, 735–742 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23502453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng J
et al.
LATS1 suppresses proliferation and invasion of cervical cancer. Mol. Med. Rep. 15, 1654–1660 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5364969</ArticleId>
            <ArticleId IdType="pubmed">28259899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He C
et al.
The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression. EMBO Mol. Med. 7, 1426–1449 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4644376</ArticleId>
            <ArticleId IdType="pubmed">26417066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y
et al.
Comprehensive molecular characterization of the Hippo signaling pathway in cancer. Cell Rep. 25, 1304–1317.e5 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6326181</ArticleId>
            <ArticleId IdType="pubmed">30380420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Xie C, Li Q, Xu K &amp; Wang E
Clinical and prognostic significance of Yes-associated protein in colorectal cancer. Tumour Biol. 34, 2169–2174 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23558963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee KW
et al.
Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients. Clin. Cancer Res. 21, 357–364 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4513664</ArticleId>
            <ArticleId IdType="pubmed">25388162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imajo M, Ebisuya M &amp; Nishida E
Dual role of YAP and TAZ in renewal of the intestinal epithelium. Nat. Cell Biol. 17, 7–19 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25531778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Genome Atlas Research Network. et al.
Integrated genomic characterization of oesophageal carcinoma. Nature
541, 169–175 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5651175</ArticleId>
            <ArticleId IdType="pubmed">28052061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muramatsu T
et al.
YAP is a candidate oncogene for esophageal squamous cell carcinoma. Carcinogenesis
32, 389–398 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21112960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song S
et al.
The Hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer. Clin. Cancer Res. 21, 2580–2590 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4452384</ArticleId>
            <ArticleId IdType="pubmed">25739674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song S
et al.
Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. Cancer Res. 74, 4170–4182 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4136429</ArticleId>
            <ArticleId IdType="pubmed">24906622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ge L
et al.
Yes-associated protein expression in head and neck squamous cell carcinoma nodal metastasis. PLoS ONE
6, e27529 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3212574</ArticleId>
            <ArticleId IdType="pubmed">22096589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eun YG
et al.
Clinical significance of YAP1 activation in head and neck squamous cell carcinoma. Oncotarget
8, 111130–111143 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5762311</ArticleId>
            <ArticleId IdType="pubmed">29340043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiemer SE
et al.
A YAP/TAZ-regulated molecular signature is associated with oral squamous cell carcinoma. Mol. Cancer Res. 13, 959–968 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4470857</ArticleId>
            <ArticleId IdType="pubmed">25794680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zender L
et al.
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell
125, 1253–1267 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3026384</ArticleId>
            <ArticleId IdType="pubmed">16814713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han SX
et al.
Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma. J. Immunol. Res. 2014, 261365 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4016924</ArticleId>
            <ArticleId IdType="pubmed">24860833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song H
et al.
Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc. Natl Acad. Sci. USA
107, 1431–1436 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2824397</ArticleId>
            <ArticleId IdType="pubmed">20080598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee KP
et al.
The Hippo–Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc. Natl Acad. Sci. USA
107, 8248–8253 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2889558</ArticleId>
            <ArticleId IdType="pubmed">20404163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fitamant J
et al.
YAP inhibition restores hepatocyte differentiation in advanced HCC, leading to tumor regression. Cell Rep. 10, 1692–1707 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4565791</ArticleId>
            <ArticleId IdType="pubmed">25772357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bueno R
et al.
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48, 407–416 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26928227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hmeljak J
et al.
Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548–1565 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6310008</ArticleId>
            <ArticleId IdType="pubmed">30322867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sekido Y
Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation. Pathol. Int. 61, 331–344 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21615608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizuno T
et al.
YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes. Oncogene
31, 5117–5122 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22286761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanahashi K
et al.
Activation of Yes-associated protein in low-grade meningiomas is regulated by merlin, cell density, and extracellular matrix stiffness. J. Neuropathol. Exp. Neurol. 74, 704–709 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26049897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baia GS
et al.
Yes-associated protein 1 is activated and functions as an oncogene in meningiomas. Mol. Cancer Res. 10, 904–913 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4703097</ArticleId>
            <ArticleId IdType="pubmed">22618028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schramm A
et al.
Mutational dynamics between primary and relapse neuroblastomas. Nat. Genet. 47, 872–877 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26121086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang M
et al.
Transcriptional co-activator TAZ sustains proliferation and tumorigenicity of neuroblastoma by targeting CTGF and PDGF-β. Oncotarget
6, 9517–9530 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4496235</ArticleId>
            <ArticleId IdType="pubmed">25940705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seong BK
et al.
A metastatic mouse model identifies genes that regulate neuroblastoma metastasis. Cancer Res. 77, 696–706 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27899382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature
489, 519–525 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3466113</ArticleId>
            <ArticleId IdType="pubmed">22960745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malik SA, Khan MS, Dar M, Hussain MU &amp; Mudassar S
TAZ is an independent prognostic factor in non-small cell lung carcinoma: elucidation at protein level. Cancer Biomark. 18, 389–395 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28128737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie M
et al.
Prognostic significance of TAZ expression in resected non-small cell lung cancer. J. Thorac. Oncol. 7, 799–807 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22481233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H
et al.
Tankyrase inhibitor sensitizes lung cancer cells to endothelial growth factor receptor (EGFR) inhibition via stabilizing angiomotins and inhibiting YAP signaling. J. Biol. Chem. 291, 15256–15266 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4946938</ArticleId>
            <ArticleId IdType="pubmed">27231341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berger AC
et al.
A comprehensive pan-cancer molecular study of gynecologic and breast cancers. Cancer Cell
33, 690–705.e9 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5959730</ArticleId>
            <ArticleId IdType="pubmed">29622464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeong W
et al.
Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. Anticancer Res. 34, 811–817 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4082822</ArticleId>
            <ArticleId IdType="pubmed">24511017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia Y
et al.
YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients. PLoS ONE
9, e91770 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3951505</ArticleId>
            <ArticleId IdType="pubmed">24622501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X
et al.
The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene
30, 2810–2822 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21317925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hua G
et al.
YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells. Oncogene
35, 2247–2265 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4791205</ArticleId>
            <ArticleId IdType="pubmed">26364602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merritt NM
et al.
A comprehensive evaluation of Hippo pathway silencing in sarcomas. Oncotarget
9, 31620–31636 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6114978</ArticleId>
            <ArticleId IdType="pubmed">30167083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eisinger-Mathason TS
et al.
Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis. Proc. Natl Acad. Sci. USA
112, E3402–E3411 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4491775</ArticleId>
            <ArticleId IdType="pubmed">26080399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Z
et al.
Structure-based design and synthesis of potent cyclic peptides inhibiting the YAP–TEAD protein–protein interaction. ACS Med. Chem. Lett. 5, 993–998 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4160762</ArticleId>
            <ArticleId IdType="pubmed">25221655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konradi AW, Lin TT-LT
Benzosulfonyl compounds
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019040380 (2018).</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
